Drug firm
Cipla Ltd on Friday said its
net profit declined by 19.49 per cent to Rs 232.69 crore for the third quarter that ended December 31, primarily due to high expenses at its Indore plant and rupee appreciation.
The company had posted a net profit of Rs 289.03 crore in the same period previous financial year, Cipla said in a filing to the Bombay Stock Exchange (BSE).
Total income of the company rose to Rs 1,579.36 crore for the reviewed period, compared to Rs 1,456.34 crore in the corresponding period previous year.
"Operating margins and profits are lower by about 16 per cent and 20 per cent, respectively, primarily on account of increased factory overheads at Indore special economic zone (SEZ) and appreciation of the Indian rupee by about 4 per cent on a year-on-year basis which has adversely affected export turnover as well as realisations," the company said.
During the quarter, the company posted a growth of 8 per cent in income from operations. Its domestic sales grew by more than 11 per cent, it added.
The company's export sales grew by about 12 per cent in spite of a rupee appreciation of about 4 per cent.
Shares of Cipla on Friday closed at Rs 324.20 on BSE, down 1.58 per cent from its previous close.
Special 
